Drug Pipeline

LCI699 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
3
Recruiting
4
Top Sponsors
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-05-22 NCT07603466 Combination Osilodrostat and Cabergoline in Cushing's Disease Phase 4 Enrolling by Invitation
Active Studies by Phase
Phase 4
2
Phase 2
2
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT07247058 Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS) Mild Autonomous Cortisol Secretion (MACS) Recruiting
NCT07603466 Combination Osilodrostat and Cabergoline in Cushing's Disease Cushing Disease Due to Increased ACTH Secretion Enrolling by Invitation
Phase 2
NCT07104812 Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) Mild Autonomous Cortisol Secretion Recruiting
NCT03708900 Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric… Cushing Syndrome Recruiting
Sponsors Running LCI699 Trials
RECORDATI GROUP (1) Mayo Clinic (1) Johns Hopkins University (1) University of Basrah (1)
Get alerts when LCI699 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free